Trial Profile
A randomized, blinded, multicenter, parallel study comparing the efficacy and safety of pulmicort [budesonide] respules at 0.5mg QD, 1.0mg QD, 1.0mg bid, 2.0mg bid and pulmicort turbuhaler at 4.00mcg bid on adolescents (12 yrs of age and older) with adults with moderate to severe asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2008
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 11 Apr 2008 New trial record.